

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 21, 2019

AMGEN INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-37702
(Commission File Number)

95-3540776
(IRS Employer
Identification No.)

**One Amgen Center Drive
Thousand Oaks, California**
(Address of Principal Executive Offices)

91320-1799
(Zip Code)

(805) 447-1000
(Registrant's Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.0001 par value	AMGN	The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting on May 21, 2019. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:

Item 1 - Election of Directors

Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company's 2020 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.

Name	Votes For	Votes Against	Abstain	Broker Non-Votes
Dr. Wanda M. Austin	454,806,146	1,042,775	1,521,000	92,311,761
Mr. Robert A. Bradway	434,709,584	17,679,520	4,980,817	92,311,761
Dr. Brian J. Druker	454,638,535	1,159,026	1,572,361	92,311,761
Mr. Robert A. Eckert	446,036,161	9,750,834	1,583,125	92,311,563
Mr. Greg C. Garland	438,192,636	17,573,215	1,603,806	92,312,026
Mr. Fred Hassan	451,550,347	4,210,825	1,608,599	92,311,911
Dr. Rebecca M. Henderson	454,742,698	1,132,209	1,498,414	92,308,361
Mr. Charles M. Holley, Jr.	454,377,748	1,366,712	1,625,937	92,311,286
Dr. Tyler Jacks	454,459,354	1,327,530	1,583,188	92,311,611
Ms. Ellen J. Kullman	451,114,136	4,752,212	1,516,591	92,298,743
Dr. Ronald D. Sugar	449,665,290	6,090,028	1,614,059	92,312,307
Dr. R. Sanders Williams	453,234,955	2,537,557	1,597,409	92,311,761

Item 2 - Advisory Vote to Approve Our Executive Compensation

The advisory vote to approve our executive compensation was approved.

For:	425,056,230
Against:	29,468,700
Abstain:	2,844,992
Broker Non-Votes:	92,311,760

Item 3 - Ratification of Selection of Independent Registered Public Accountants

Ernst & Young LLP was ratified as the Company's independent registered public accountants for the fiscal year ending December 31, 2019. No Broker Non-Votes resulted from the vote on this proposal.

For:	528,869,016
Against:	18,874,776
Abstain:	1,937,891

No other matters were submitted for stockholder action.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMGEN INC.

Date: May 21, 2019

By: /s/ Jonathan P. Graham
Name: Jonathan P. Graham
Title: Senior Vice President, General Counsel and
Secretary